30 closest matches · ranked by relevance
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
AML
Primary: Complete Response Rate — 19 Participants
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Leukemia, Myeloid, Acute
Primary: Determination of the Maximum Tolerated Dose (MTD) of BI 836858 — NA; NA Milligram (mg)
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Acute Myeloid Leukemia · Acute Myeloid Leukemia, in Relapse · Acute Myeloid Leukemia Refractory
Primary: Maximum Tolerated Dose (MTD) — 5; 5; 2 participants
Leukemia
Primary: Number of Patients With Natural Killer (NK) Cell Expansion — 2 Participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 · Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Primary: Participants With a Response — 3 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants
Leukemia, Myeloid
Primary: Number of Participants Who Achieved a Morphologic Complete Response Within the First Four Cycles of Lenalidomide Treatment According to the Modified International…
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Myeloid Leukemia in Remission · Blasts Under 10 Percent of Bone Marrow Nucleated Cells
Primary: Recurrence-free Survival Rate — 8.5 Months
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants
Acute Myelogenous Leukemia
Primary: Number of Participants With Relapse-Free Response at 1 Year — 10; 10 participants
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia
Primary: Recommended Phase II Dose (RP2D) of 8-Chloro-adenosine (8-Cl-Ado) — 400 mg/m^2
Acute Myeloid Leukemia Post Cytotoxic Therapy · Recurrent Childhood Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Number of Participants With a Dose-limiting Toxicity — 1 Participants
Adult Acute Megakaryoblastic Leukemia · Adult Acute Monoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Response Rate(CR/CRi) Rate — 6; 9 participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants
Acute Myeloid Leukemia
Primary: Summary of Best Modified Criteria Response Results, Bridged-to-Transplant (BTT) Participants, and Composite Remission Rates in Patients on Treatment With PLX3397 (Dose…
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome
Primary: Number of Participants With Dose Limiting Toxicities of MLN4924 (Pevonedistat) — 1; 2 Participants
Acute Myeloid Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine
Lymphoblastic Leukemia, Acute, Childhood · Myelogenous Leukemia, Acute, Childhood
Primary: The Dose of AC220 That is Safe and Biologically Active When Given in Sequential Combination With Ara-C/Etoposide — 0; 3; 1; 4 Participants
Acute Myeloid Leukemia
Primary: Number of Participants With Adverse Events (Safety Profile) — 6; 13; 2; 11 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Number of Participants With a Response of CR, CRp, or PR — 0; 1; 0 participants